This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Immunology  • Oncology  • Head & Neck Cancer  • Neoplasms of Head & Neck  • Alert me on articles by topic

Stephen Jo, MD; Michael J. Babb, MD; Raymond L. Hilsinger, Jr, MD

Arch Otolaryngol Head Neck Surg. 2006;132:1257-1259.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Interdigitating dendritic cell sarcoma (IDCS) is a malignant neoplasm that arises from the interdigitating reticular cells of the lymph node. Dendritic cells are a heterogeneous group of antigen-presenting cells that play a major role in innate and adaptive immune responses. Subtypes of dendritic cells include Langerhans cells, interdigitating dendritic cells, follicular dendritic cells, and dermal dendrocytes.¹ Interdigitating dendritic cells reside in the T-cell areas of peripheral lymphoid tissue, including the paracortex of lymph node and tonsil, the splenic periarteriolar lymphoid sheaths, and the interfollicular areas of mucosa-associated lymphoid tissue, and are responsible for major histocompatibility complex–restricted stimulation of resting T cells. Interdigitating dendritic cell sarcoma is rare; to our knowledge, only 34 cases have been reported to date.^1-4 Lymphadenopathy is the most common physical finding at presentation, and 42% of cases occur in the head and neck.^1-2,4 Otolaryngologists . . . [Full Text of this Article]

REPORT OF A CASE

COMMENT

CONCLUSIONS

AUTHOR INFORMATION

Author Affiliations: From the Department of Head and Neck Surgery, Kaiser Permanente Medical Center, Oakland, Calif. Dr Babb is now in private practice, Redding, Calif.